Echo Therapeutics Presents Positive Clinical Trial Results of the Symphony tCGM System at the American Diabetes Association's 72nd Scientific Sessions

Echo Therapeutics, Inc.

presented an expanded analysis of data collected from subjects with either type 1 or type 2 diabetes during its recent clinical trial of its Symphony tCGM System. The data were presented during an oral presentation session on Friday, June 8 at the 72nd Annual Scientific Sessions of the American Diabetes Association (ADA) in Philadelphia, PA. The presentation [ADA abstract 007-OR], entitled "Transdermal Continuous Glucose Monitoring Following Skin Permeation," by Wayne Menzie, Echo's Director of Technology and Clinical Development, provided data from twenty (20) adult subjects with type 1 or type 2 diabetes whose glucose levels were monitored continuously for 24 hours.